… % of vedolizumab patients at weeks 26 and 52, respectively. Endoscopic remission was greater
in patients naïve to anti-TNF agents than patients … in patients with active Crohn's disease …

… The difference between mean baseline and mean Week 52 total Inflammatory Bowel
Disease Questionnaire scores was 48.7 points for patients receiving vedolizumab SC and 39.7 …

… in vedolizumab patients was largely due to gastroenteritis. Rates of gastroenteritis with
vedolizumab and placebo, respectively, were 3.7/100 PYs and 0/100 PYs in patients with UC and …

… effects of combining vedolizumab with immunosuppressive agents. In conclusion, patients
with moderately to severely active Crohn's disease who were treated with vedolizumab, as …

… Inflammatory bowel disease (IBD) is a disorder of … ulcerative colitis (UC) and Crohn’s disease
(CD) [1, 2]. The prevalence of IBD in elderly patients is high, with 10–30% of the global IBD …

… We identified a low rate of success of vedolizumab in patients with active perianal Crohn's
disease, and nearly one third of patients with inactive perianal Crohn's disease had perianal …

… (CD) is one of two main forms of inflammatory bowel disease (IBD) (the second one is … of
vedolizumab over placebo in patients with CD. Our analysis supports the use of vedolizumab for …

… or Crohn’s disease. This article reviews the pharmacological properties of intravenous
infusions of vedolizumab and its clinical efficacy in adult patients with these diseases. In phase III …

… and baseline patient characteristics All patients being treated with vedolizumab in our
geographic uptake area were included in this study, resulting in a cohort of 182 patients (UC: 97 (…

… Although anti-TNF agents have positively impacted the treatment of inflammatory bowel
disease, many patients can lose their response or develop intolerance to these agents over time …